The mechanism of action of bedaquiline fumarate (Sneril)

Bedaquiline fumarate (Bedaquiline) is a drug used to treat multidrug-resistant tuberculosis (MDR-TB). Its mechanism of action mainly involves its effect on the metabolism of Mycobacterium tuberculosis cells. The following is a brief description of fumaric acidbedaquiline (Sneril) mechanism of action:

1.Inhibition of ATPsynthesis: fumaric acidbedaquiline (Sneril) through enzymes related to ATP synthesis of Mycobacterium tuberculosis ATPsynthase (ATP synthase) binds and blocks the synthesis of ATP in bacterial cells. ATPsynthesis is a necessary energy source for the survival and proliferation of bacterial cells. Therefore, the effect of fumaric acidbedaquiline (Sneril) causes bacterial energy metabolism disorders, thus affecting the viability of bacteria.

2.Interfering with membrane potential: Fumaric acid Bedaquiline (Sneril) may also exert its antibacterial effect by interfering with the potential of bacterial cell membranes. The cell membrane of Mycobacterium tuberculosis is one of the important structures necessary to maintain bacterial survival, and fumaric acidbedaquiline (Sneril) may disturb the integrity of the bacterial cell membrane by interfering with the membrane potential, thereby causing bacterial death.

3.Selective effect: Fumaric acid Bedaquiline (Sneril) is relatively selective in its effect on Mycobacterium tuberculosis. Its mechanism of action mainly affects the survival and proliferation of bacteria, but has a relatively small impact on host cells. This allows fumaric acidbedaquiline (Sneril)to clear bacteria more efficiently without causing excessive damage to host cells.

In general, fumaric acidbedaquiline (Sneril) affects the viability of Mycobacterium tuberculosis by inhibitingATP synthesis and interfering with bacterial cell membrane potential, thereby exerting its anti-tuberculosis effect. This mechanism of action makes fumaric acidbedaquiline (Sneril) one of the important drugs for the treatment of multidrug-resistant tuberculosis, providing a new option for the treatment of tuberculosis.